Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tempest Therapeutics, Inc. - Common Stock (NQ:TPST)

3.136 -0.064 (-2.00%)
Streaming Delayed Price Updated: 2:32 PM EST, Nov 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 191,392
Open 3.160
Bid (Size) 3.130 (100)
Ask (Size) 3.140 (2,800)
Prev. Close 3.200
Today's Range 3.030 - 3.240
52wk Range 3.010 - 13.65
Shares Outstanding 11,586,406
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
$4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of short-term unregistered warrants 
From Tempest Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga

Performance

YTD
-71.9%
-71.9%
1 Month
-71.5%
-71.5%
3 Month
-71.4%
-71.4%
6 Month
-49.3%
-49.3%
1 Year
-73.6%
-73.6%

More News

Read More
News headline image
Tempest Therapeutics Stock Plummets Nearly 50% Amid Shareholder Dilution Fears Following CAR-T Acquisition
Via MarketMinute
News headline image
TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction ↗
Via Stocktwits
News headline image
Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
Nasdaq Gains Over 100 Points; Target Trims Earnings Forecast ↗
Via Benzinga
News headline image
Why Tempest Therapeutics (TPST) Stock Is Down 45% Today ↗
Via Benzinga
News headline image
Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga
News headline image
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
From Tempest Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Why Circle Internet Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Get insights into the top gainers and losers of Monday's pre-market session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success ↗
Via Benzinga

Frequently Asked Questions

Is Tempest Therapeutics, Inc. - Common Stock publicly traded?
Yes, Tempest Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Tempest Therapeutics, Inc. - Common Stock trade on?
Tempest Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Tempest Therapeutics, Inc. - Common Stock?
The ticker symbol for Tempest Therapeutics, Inc. - Common Stock is TPST on the Nasdaq Stock Market
What is the current price of Tempest Therapeutics, Inc. - Common Stock?
The current price of Tempest Therapeutics, Inc. - Common Stock is 3.136
When was Tempest Therapeutics, Inc. - Common Stock last traded?
The last trade of Tempest Therapeutics, Inc. - Common Stock was at 11/26/25 02:32 PM ET
What is the market capitalization of Tempest Therapeutics, Inc. - Common Stock?
The market capitalization of Tempest Therapeutics, Inc. - Common Stock is 36.33M
How many shares of Tempest Therapeutics, Inc. - Common Stock are outstanding?
Tempest Therapeutics, Inc. - Common Stock has 36M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.